This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Aegerion Pharmaceuticals Announces First-Quarter 2013 Financial Results

For additional disclosure regarding these and other risks we face, see the disclosure contained in the "Risk Factors" section of Aegerion's Annual Report on Form 10-K filed on March 18, 2013, and our other public filings with the Securities and Exchange Commission, available on the SEC's website at . We undertake no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.

Aegerion Pharmaceuticals, Inc. 
Condensed Consolidated Statements of Operations 
  Three Months Ended March 31,
(In 000s) 2013 2012
Net product sales  $ 1,231  $ -- 
Cost of sales  183  -- 
Operating expenses:    
Selling, general and administrative  13,220 5,111
Research and development  5,775  4,635
Restructuring costs  1  831
Total operating expenses  18,996  10,577
Loss from operations  (17,948) (10,577)
Interest expense, net  (149) (286)
Other expense, net  (45) (802)
Net loss  $ (18,142)  $ (11,665)
Net loss per common share - basic and diluted  $ (0.64)  $ (0.55)
Weighted-average shares outstanding - basic and diluted  28,337  21,246
Aegerion Pharmaceuticals, Inc. 
Condensed Consolidated Balance Sheets 
(In 000s) March 31, 2013 December 31, 2012
Cash, cash equivalents and marketable securities  $ 140,689  $ 82,177
Accounts receivable, net  763  -- 
Inventory  841  -- 
Prepaid expenses and other current assets  2,233  1,571
Restricted cash  105  105
Property and equipment, net  1,236  1,143
Other assets  93  93
Total assets  $ 145,960  $ 85,089
Accounts payable and accrued expenses  $ 8,732  $ 13,904
Current portion of long-term debt  3,578  3,022
Long-term debt  6,695  7,589
Other noncurrent liabilities  190  173
Total liabilities  19,195  24,688
Total stockholders' equity  126,765  60,401
Total liabilities and stockholders' equity  $ 145,960  $ 85,089
CONTACT: Aegerion Pharmaceuticals, Inc.
         Amanda Murphy
         Manager, Investor Relations
         (857) 242-5024

Aegerion Pharmaceuticals, Inc. Logo

4 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,084.49 +33.74 0.20%
S&P 500 2,014.89 +15.91 0.80%
NASDAQ 4,830.47 +19.6820 0.41%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs